Clinical trial of anti-platelet-derived growth factor combined with ranibizumab in the treatment of patients with age-related macular degeneration
10.13699/j.cnki.1001-6821.2018.08.005
- VernacularTitle:抗血小板源性生长因子联合雷珠单抗治疗年龄相关性黄斑变性的临床研究
- Author:
Zhong-Yang YAN
1
;
Min DONG
;
Na YANG
;
Ya-Lin LI
;
Cheng-Quan LI
;
Li-Fei WANG
Author Information
1. 河北省眼科医院眼底外科
- Keywords:
age-related macular degeneration;
ranibizumab;
levamlodipine besylate;
vascular endothelial growth factor;
platelet-derived growth factor-B
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(8):930-933
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of anti-platelet-derived growth factor combined with ranibizumab in the treatment of patients with age-rclated macular degeneration.Methods A total of 58 cases of age-related macular degeneration were randomlv divided into control group (29 cases) and treatment group (29 cases).The two groups were treated with intravitreal injection with 10 mg · mL-1 ranibizumab,each time 0.05 mL,1 time a month for 3 months.The treatment group was also orally given levamlodipine besylate 5 mg,1 times a day for 3 months.The patients were followed up for 6 months after treatment.The best corrected visual acuity,central macular thickness,fundus hemorrhage area,fluorescein leakage area,and complication rate were measured and analysed.Results After treatment,the total effective rates in control group and treatment group were 72.41％ (21 cases/29 cases),92.59％ (25 cases/27 cases),with significant difference (P ＜0.05).The total improvement rates in control group and treatment group were 75.86％ (22 cases/29 cases),96.30％ (26 cases/27 cases),with significant difference(P ＜ 0.05).After treatment,the corrected visual acuity of control group and treatment group were 0.27 ± 0.08,0.34 ± 0.06,the thickness of the macular fovea were (419.90 ± 30.91),(395.67 ± 6.49) μm,the area of fundus hemorrhage were (0.31 ± 0.13),(0.22 ± 0.06) mm2,and fluorescein leakage area were (0.95 ± 0.17),(0.86 ± 0.13)mm2,all with significant difference (all P ＜ 0.05).The adverse drug reactions in treatment group and control group were high intraocular pressure,conjunctival bleeding and vitreous floating.The incidence of adverse drug reactions in control group and treatment group were 27.59％ (8 cases/29 cases),22.22％ (6 cases/27 cases),with no significant difference (P ＞ 0.05).Conclusion Anti-platelet-derived growth factor can improve the clinical efficacy of ranibizumab in the treatment of age-related macular degeneration.
